Novo Nordisk GLP-1 rece...
Novo Nordisk recently released data on the ELLipsE pha...
[2019/04/30]READLINE was established in 2013. The company is headquartered in the "National Science and Technology Business Incubator" in Shenzhen Nanshan Hi-tech Industrial Park. It is an innovative group company integrating R&D, production, sales, and investment. There are three subsidiaries in the group company: Shenzhen Readline Biotechnology Co., Ltd. which focuses on the applications of immobilized enzymes technology, Shenzhen Readline Technology Co., Ltd.
了解更多>>The immobilized enzyme technology is applied in the fields of peptides, polysaccharides and non-natural amino acids, the developed products are applied in medicine, health care products, cosmetics, food, feed and other industries.
Focus on the export trade of high-quality products in Chinese peptide industry chain and realize the one-stop procurement of polypeptide products by international customers.
Focus on venture capital investments in healthcare. At present, the company has cultivated the integration of Chinese peptide industry chain and realized the competitive advantage of Chinese peptide enterprises in the world.
Undertake international innovative medical equipment, medicine and medical services in Chinese market-oriented business; provide domestic legal advice and regulations for international customers consultation; provide undertaking of product access; recommend partners; assist to sign the relevant documents of rights and interests, etc.
Novo Nordisk recently released data on the ELLipsE pha...
[2019/04/30]Recently, a research paper entitled Inhibiting PD-L1 pa...
[2019/04/08]CENTER FOR DRUG EVALUATION AND RE...
[2019/01/10]Mylan Prevails in Copaxone® 40mg/mL Litigation Agains...
[2018/11/27]